Curriculum VitaeDate January 2005

James Eric Udelson, M.D., F.A.C.C.

Associate Chief, Division of CardiologyDirector, Nuclear Cardiology Laboratory

Co-Director, Heart Failure and Cardiac Transplant CenterCo-Director, Hypertrophic Cardiomyopathy Center

Department of Medicine/Division of CardiologyTufts-New England Medical Center

Associate Professor of Medicine and RadiologyTufts University School of Medicine

Office Address: Tufts-New England Medical Center Department of Medicine/Division of Cardiology750 Washington StreetNEMC #70Boston, MA 02111

Office Phone Number: 617-636-8066 Fax: 617-636-2276E-mail Address: JUdelson@tufts-nemc.org

Date of Birth: December 16, 1955

EDUCATION

1977 Bachelor of Arts, Chemistry, cum laudeWesleyan University, Middletown, Connecticut

1981 Doctor of MedicineNew York Medical College, Valhalla, New York

POSTDOCTORAL TRAINING

1981-84 Intern and Resident, Internal MedicineNewton Wellesley Hospital, Newton, MassachusettsChief Medical Resident, 1983-84

1984-85 Attending Physician, Internal MedicineLemuel Shattuck Hospital, Boston, Massachusetts

1985-87 Medical Staff Research Fellowship, Cardiology BranchNational Heart, Lung, and Blood InstituteNational Institutes of Health, Bethesda, Maryland

1987-89 Cardiology FellowshipDivision of Cardiology, New England Medical Center Hospitals, Tufts University School of Medicine, Boston, Massachusetts

LICENSURE AND CERTIFICATION

1984 American Board of Internal Medicine

1989 Subspecialty Boards in Cardiovascular Disease

ACADEMIC APPOINTMENTS

1989-1995 Assistant Professor of Medicine and RadiologyTufts University School of Medicine

1995- Associate Professor of Medicine and RadiologyTufts University School of Medicine

HOSPITAL APPOINTMENTS

1989-present Director, Nuclear Cardiology Laboratory1990-1997 Associate Director, Cardiac Catheterization Laboratory1989-present Co-Director, Heart Failure and Cardiac Transplant Center1994-present Director, Cardiac Imaging Core Laboratory1998-present Associate Chief, Division of Cardiology2002-present Co-Director, Hypertrophic Cardiomyopathy Center

AWARDS AND HONORS

1984 Derby Hematology/Oncology Award, Newton-Wellesley Hospital, Newton, Mass.1987 American College of Cardiology Syntex Award1988 American College of Cardiology Bristol Labs Award1991 Young Investigator Award - Stipend to attend first state-of-the-art Nuclear Cardiology

Conference, Wintergreen, VA 1998,1999,2000 Tufts University School of Medicine Excellence in Teaching Award from Second Year

Medical Students1999 NEMC Oliver Platt Award recommended by patients2001-2002 Tufts University School of Medicine Excellence in Teaching Award/Medical Clerkship from

Third Year Medical Students

HOSPITAL, MEDICAL SCHOOL, UNIVERSITY COMMITTEE ASSIGNMENTS

Department of Medicine Intern Selection Committee 1990-1998Division of Cardiology Fellow Selection Committee 1989 - presentNew England Medical Center—Medical Advisory Delay Occurrence GroupNew England Medical Center—Physician Quality of Life Survey CommitteeTufts Medical Student Internal Medicine AdvisorNew England Medical Center—Radiation Safety Committee 1990-presentDepartment of Medicine - Intern MentorDepartment of Medicine – Committee on Clinical Research Activities - ongoing

OTHER MAJOR COMMITTEE ASSIGNMENTS

1) National Institutes of Health/NHLBI Clinical Trials Branch – Ad hoc Grant Reviewer2) Tufts Health Plan - Cardiology Liaison Committee 1995- present3) Member, Medical Imaging Drug Advisory Committee (MIDAC), Center for Drug

Evaluation and Research, United States Food and Drug Administration, 2001-2004

TEACHING RESPONSIBILITY

2

Tufts University School of Medicine first/second year students—Research selective tutorial “Topics in Cardiology Research”Tufts University School of Medicine second year students—Pathophysiology course (cardiovascular)-lectures and workshopsTufts University School of Medicine third/fourth year students—Ward rotations in cardiologyDepartment of Medicine second/third year residents—Morning reportDivision of Cardiology—Fellowship trainingWesleyan University—Pre-medical student preceptorship program

PROFESSIONAL SOCIETIES

Fellow, American College of CardiologyAmerican Heart AssociationAmerican Heart Association Council on Clinical CardiologyAmerican Heart Association – New England AffiliateAmerican College of Cardiology-Massachusetts ChapterAmerican Society of Nuclear CardiologyHeart Failure Society of AmericaAssociation of University CardiologistsCertification Board of Nuclear Cardiology

OFFICE AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES

American Society of Nuclear CardiologyNewsletter Committee, Chair, 1995-2000Editor, Newsletter, 1996-2000Board of Directors, 1996-presentPublications Committee 1996-2000Annual Scientific Session Program Committee, Chair 1997-1998Annual Scientific Session Organizing Committee 1998-2001Executive Committee 1997-2003Vice-President 1997-1998Secretary 1998-1999President-Elect 1999-2000President 2000-2001Chair, Nominating Committee, 2001-2002Chair, Awards Committee, 2001-2002Biennial Invitational State-of-the-Art Conference, Co-Chair2000-2006

American College of CardiologyCardiovascular Imaging Committee 1998-2000Chair, Cardiovascular Imaging Committee 2000-2003Cardiovascular Subspecialty Societies Leadership Group Member 1999-2001Annual Scientific Session Program Committee Member 2000-2002Annual Scientific Sessions Program Committee 2000-2005

Co-Chair, Nuclear Spotlight Planning Committee 2000-2005 ACC Representative to the Certification Board of Nuclear Cardiology

Representative 2000-2004Bethesda Conference #34 Steering Committee: Can Atherosclerosis

Imaging Techniques Improve the Detection of Patients at Risk for Ischemic Heart Disease? Co-Chair 2001-2003

Echocardiography Committee ex officio 2000-2003

3

ACC/AHA Task Force on Practice Guidelines - ACC/AHA/ASNC Writing Committee to Revise the 1995 Guidelines for Clinical Use of Cardiac Radionuclide Imaging 2000 - 2003

Publications Committee Member 2003-2006Journal of the American College of Cardiology Editorial Board

Editorial Consultant 2003-2005Journal of the American College of Cardiology – Invited Guest

Editor 2003-Bethesda Conference #36: Recommendations for Determining for

Competition in Athletes with Cardiovascular Abnormalities Task Force Member 2003-2005

Board of Trustees 2005 - -

Certification Board of Nuclear CardiologyBoard of Directors 1999-2004Vice-Chair, 2000-2004

Society of Nuclear MedicineBoard of Directors, Cardiovascular Council 1996-1998

American Heart Association, Massachusetts AffiliateContinuing Education Committee - Chairman, 1993-1996Peer Review Grant Committee, 1991-1995Program Council 1994-1997Research Committee 1994-1998

American College of Cardiology, Massachusetts AffiliateCouncilor 1994-1996Mass ACC consultant to Blue Cross/Blue Shield of Massachusetts on

credentialing guidelines for Nuclear Cardiology

American Heart Association - Council on Clinical Cardiology Cardiac Imaging Committee 1997-2000

MAJOR RESEARCH INTERESTS

Physiology/pathophysiology of ventricular performancePharmacotherapy of heart failureCardiovascular imaging

4

EDITORIAL BOARDS AND ACTIVITY

Associate Editor, Circulation, 2004- Invited Guest Editor - Journal of the American College of Cardiology

Invited Guest Editor - Journal of Nuclear Cardiology

Manuscript Referee - New England Journal of MedicineJAMACirculationJournal of the American College of CardiologyJournal of Nuclear CardiologyAmerican Heart JournalAmerican Journal of CardiologyJournal of Cardiac FailureJournal of Nuclear MedicineAmerican Journal of PhysiologyInternational Journal of Cardiology

Editorial BoardJournal of Nuclear Cardiology Editorial Board 1997-Journal of the American College of Cardiology 2003 - Theheart.org 2000-

FUNDED RESEARCH PROTOCOLS

Extramural Funding

1) Title: Validation of a Low Cost Portable Cardiac First Pass CameraContract: National Institutes of Health, Small Business Innovated Research (SBIR) Grant: Proportional Technologies Inc, Houston TXRole: Site Principal Investigator, one of five US sites subcontracted to work on validation of this new camera with an onboard generatorPeriod 1997-1998.

2) Title: Assessment of Sestamibi Imaging in Emergency Department Chest Pain PatientsGrant: Agency for Health Care Policy and Research/DHHS RO1-HS090110-01Role: Co-Principal Investigator of six center, 2,500 patient study, a randomized trial of an ED strategy incorporating perfusion imaging compared to a standard strategy in chest pain patients with non-diagnostic ECG's.Period: 1996-1999

3) Title: The PERL Study – Prevention by estrogen of restenosis in elderly women after PTCA/stentingGrant: National Institute on Aging/NIH (P.I. Douglas Losordo)Role: SPECT perfusion imaging core laboratory directorPeriod: 1999-2000

4) Title: Effects of selective estrogen receptor modulation on left ventricular remodeling, endothelial function and electrophysiologic parametersGrant: RO1 from National Heart, Lung and Blood Institute

5

Role: Principal Investigator, as part of a Specialized Center of Research (SCOR) grant program. A single center, randomized trial of the selective estrogen receptor modulator raloxifene on ventricular remodeling, endothelial function, and electrophysiologic endpoints. Period: 2000-2004

5) Title: Myocardial Viability and Left Ventricular Remodeling in the Occluded Artery TrialGrant: RO1 HL075456-01 NHLBIRole: Principal Investigator; ancillary study to the NHLBI funded Occluded Artery Trial, examining the influence of infarct zone viability by radionuclide techniques on post-MI left ventricular remodeling. Includes 200 patients studied at 40 international sites.Direct cost: $1,810,599, period 2004-2007

6) Title: Left ventricular function Core Laboratory for the IMMEDIATE TrialGrant RO1 XXXXX NHLBIRole: Principal Investigator, ancillary study to the 14,000 pt IMMEDIATE Trial, assessing the effect of immediate glucose-insulin-potassium given in ambulances and Emergency Department for acute coronary syndromes. Ancillary study will investigate mechanisms of GIK effect, by measuring infarct size, LV function, and other biomarkers in a subset of patients from the IMMEDIATE Trial.Direct cost Y1 XXXXXXX, total direct cost for funding period XXXXXXXX, period XXXXX

Radionuclide Core Laboratory Studies

Director, Cardiac Imaging Core LaboratoryDivision of Cardiology

– central analysis of therapeutic effects on perfusion and ventricular function/volumes for multicenter clinical trials

1) Title: Beta Blocker Evaluation of Survival Trial (BEST)Contract: NIH/VA Cooperative Studies ProgramRole: Core Laboratory Director, acting as the quality control core lab for radionuclide studies done in the BEST trial, re-analyzing approximately 800 radionuclide ventriculograms from ~100 US and Canadian sites for quality and ejection fraction.Period: 1996-1999

2) Title: Prospective Randomized Amlodipine Survival Evaluation–2 (PRAISE 2), radionuclide substudy core lab. Contract: Pfizer, Inc.Role: Principal Investigator of Radionuclide Substudy, evaluating changes in ventricular volumes and ejection fraction in 100 patients from 15 selected sites in the PRAISE 2 trial, investigating the role of amlodipine in non-ischemic cardiomyopathy.Period: 1996-2000

3) Title: Inhibition of Metalloprotease Exercise Study (The IMPRESS trial), radionuclide substudy core laboratory.Contract: Bristol-Meyers SquibbRole: Principal Investigator of Radionuclide Substudy Core Lab, evaluating changes in ventricular volumes and ejection fractions from treatment with Omaparilat, a dual metalloprotease inhibitor in heart failure patients, 120 patients from 20 selected sites in the US and Canada.Period: 1997-2000

6

4) Title: Comparison of Nycomed Echo Contract Perfusion Agent to Sestamibi SPECT Imaging For Detection and Localization of Myocardial Infarction, core laboratory.Contract: Nycomed Inc.Role: Nuclear Core Lab Principal Investigator, evaluating qualitative and quantitative resting SPECT perfusion imaging from two centers (one US and one European) compared to a new echo contrast agent.Period: 1997-1998

5) Title: The Use of Nycomed Perfusion Contrast Echo to Assess Wall Motion and Ejection FractionContract: Nycomed Inc.Role: Principal Investigator of Nuclear Core Lab, to assess radionuclide ventriculography (RVG) wall motion and ejection fraction in comparison to echocardiographic studies using the Nycomed contrast echo agent.Period: 1997-1998

6) Title: MIBI or Thallium in Viability Evaluation (The MOTIVE Trial), radionuclide core laboratoryContract: Dupont RadiopharmaceuticalsRole: Principal Investigator of five center study comparing thallium and sestamibi for evaluation of myocardial viability, principal investigator of core lab for analysis of all SPECT perfusion scans and RVG's (approximately 500 scans).Period: 1996-1999

7) Title: Emergency Department Evaluation of Sestamibi ImagingContract: Wayne State UniversityRole: Re-analysis and Quality Control of SPECT sestamibi perfusion scans performed in this trial at Wayne State University under the direction of Robert Zalenski, M.D. Period: 1997-1998

8) Title: Effect of recombinant fibroblast growth factor (rFGF) on myocardial perfusion in chronic coronary artery diseaseContract: Chiron CorporationRole: Blinded analysis of myocardial perfusion SPECT images in 59 phase 1 patientsPeriod: 1999

9) Title: Effect of recombinant fibroblast growth factor (rFGF) on myocardial perfusion in chronic coronary artery diseaseRole: Core laboratory Director for myocardial perfusion SPECT image analysis for phase 2 trial, receiving/translating/blindly analyzing ~990 SPECT scans from 35 sites Period: 1998-2000

10) Title: Effect of Herceptin on breast cancer – multicenter trialContract: GenentechRole: Core laboratory director for RVG analysis of LV function changes before and during Herceptin therapy, in approximately 60 patients at 10 sitesPeriod: 1999-2001

11) Title: Comparison of SPECT myocardial perfusion and contrast echocardiographyContract: AcusphereRole: Core laboratory Director for SPECT perfusion imaging blinded analysisPeriod: 2000-2

7

12) Title: Phase 1 study of adenovirus mediated angiogenic gene transfer as adjunct to CABG in advanced CADContract: Genzyme Corporation Role: SPECT perfusion imaging core laboratoryPeriod: 2000-2004

13) Title: The PERL study – effect of estrogen on restenosis in elderly women undergoing PTCA/stentingGrant: National Institute on Aging/NIHRole: SPECT perfusion imaging core laboratoryPeriod: 1999-2000

13) Effect of metabolic modulation with ranolazine on cardiac function in patients with heart failureContract: CV TherapeuticsRole: Core lab director for LVEF determinations from 15 US centersPeriod: 2000-2002

14) Effect of Percutaneous Intercoronary Veno-Arterial Anastamosis on myocardial perfusion by SPECT imagingRole: Core lab directorMultiple non-US centersPeriod: 2000-2002

15) Effect of the vasopressin receptor antagonist tolvaptan on LV remodeling in heart failure.Contract: Otsuka Maryland Research Institute.Role: Steering Committee Chairman and Core lab director. Assessment of serial changes in LV/RV volumes in 240 patients at 40 centers.Period: 2002-2004

16) Gated SPECT imaging in heart failure. Contract: BMS Medical Imaging

Role: Steering Committee Chair and Core lab director. Assessment of myocardial perfusion and LV function in 200 patients with new onset heart failure, from 15 centers in US and UK.Period: 2001-2003

17) Effect of epleronone on LV remodeling in patients with mild-to-moderate heart failure. Contract: Pfizer

Role: Steering Committee member and Core lab director. Assessment of serial changes in LV/RV volumes in 250 patients at 35 centers.Period: 2002-2004

Prior/Ongoing Funded Research Protocols

1) Title: The Use of Thallium201 Reinjection Following Dipyridamole Stress TestingGrant: DuPont RadiopharmaceuticalsRole: Principal InvestigatorPeriod: 1991-1992

2) Title: A Quantitative Analysis Database for Two-Day Sestamibi Imaging ProtocolsGrant: DuPont RadiopharmaceuticalsRole: Site Principal InvestigatorPeriod: 1991-1992

8

3) Title: The Use of Intravenous Nitroglycerin to Enhance the Evaluation of Myocardial Viability in Left Ventricular Dysfunction with SestamibiGrant: DuPont RadiopharmaceuticalsRole: Principal InvestigatorPeriod: 1992-1993

4) Title: The Use of Radiolabeled Antimyosin Antibodies to Detect Myocardial Necrosis Induced by Radiofrequency Ablation TechniquesGrant: McNeil PharmaceuticalsRole: Co-Principal InvestigatorPeriod: 1992-1993

5) Title: A Multicenter Trial to Evaluate the Use of Arbutamine as a Pharmacologic Stress Agent for Myocardial Perfusion ImagingGrant: Gensia PharmaceuticalsRole: Site Principal InvestigatorPeriod: 1992-1993

6) Title: The Use of Variance Cardiography to Detect Coronary Disease in the Resting State: Comparison with Stress Myocardial Perfusion ImagingGrant: Vital Heart SystemsRole: Principal InvestigatorPeriod: 1992-1994

7) Title: Evaluation of Amlodipine Effects on Exercise Tolerance in Mild to Moderate Heart Failure and Left Ventricular DysfunctionContract: Pfizer, Inc.Role: Site Principal InvestigatorPeriod: 1991-1993

8) Title: Prospective Randomized Evaluation of Flosequinan Longevity Evaluation, Multicenter TrialContract: Boots PharmaceuticalsRole: Site Principal InvestigatorPeriod: 1991-1993

9) Title: Multicenter Trial Evaluating the Beta-Blocker/Vasodilator Carvedilol in Mild to Moderate Heart FailureContract: Smith Kline BeechamRole: Site Principal InvestigatorPeriod: 1993-1995

10) Title: Correlation of Quantitative SPECT Scintigraphy and Regional Tissue Uptake of Technetium-99m Sestamibi in Ischemic Myocardium with Myocardial Metabolism and Improvement in Dyssynergic Myocardial Segments Following Coronary Revascularization SurgeryGrant from the Society of Nuclear Medicine to Luke Daley, MD, fellowship traineeRole: Research SupervisorPeriod: 1993-1994

11) Title: A Multicenter Trial Analyzing the Roles of Thallium201 and Sestamibi in Predicting Reversibility of Regional Ventricular Dysfunction in Chronic Coronary Artery DiseaseGrant: DuPont RadiopharmaceuticalsRole: Principal Investigator of multicenter study (5 sites), NEMC Site Principal InvestigatorPeriod: 1995-1997

9

12) Beta Blocker Evaluation of Survival Trial (BEST)Contract: NIH/VA Cooperative Studies ProgramRole: Site Principal InvestigatorPeriod: 1996-1999.

13) Title: Effect of dual vasopressin receptor antagonist conivaptan on hemodynamic in advanced heart failure Grant: Parke-DavisRole: Executive Steering Committee, site principal investigatorPeriod: 1999-2000

14) Effect of conivaptan on exercise tolerance and oxygen uptake in CHF: the ADVANCE trialGrant: Parke-DavisRole: Site Principal InvestigatorPeriod: 1999-2000

15) A Multicenter, Randomized, Active-Control, 2-Phase, Crossover Study of Pharmacological Stress Induced by MRE0470 Versus Adenosine in Patients with Known or Suspected Coronary Artery Disease Referred for Myocardial Radionuclide ImagingRole: Chair, Steering Committee and Study Principal Investigator for 2 phase 3 multinational pivotal trials, ~1,200 patients 2003-2005Sponsor: King Pharmaceuticals

16) Effect of the vasopressin receptor antagonist tolvaptan on LV remodeling in heart failure.Role: Chair Steering Cmte. Assessment of serial changes in LV/RV volumes in 240 patients at 40 centers. Contract: Maryland Research InstitutePeriod: 2002-2004

17) Effect of epleronone on LV remodeling in patients with mild-to-moderate heart failure. Contract: Pfizer

Role: Steering Committee member and Core lab director. Assessment of serial changes in LV/RV volumes in 250 patients at 35 centers.Period: 2004-2006

SPECIAL PROJECTS and AWARDS

1) Named among "Boston's Best Doctors" (Cardiology), Boston Magazine, Feb., 19972) Founder and co-director of Cardiovascular Clinical Studies , LLC, an academic research coordinating

center3) Invited member, Medical Imaging Drug Advisory Committee (MIDAC), Center for Drug Evaluation and

Research, United States Food and Drug Administration, 2001-2004

10

James E. Udelson, M.D., F.A.C.C.BIBLIOGRAPHY

Refereed Manuscripts in Peer-Reviewed Journals

1. Udelson JE, Cannon RO, Bacharach SL, Rumble TF, Bonow RO. Beta-adrenergic stimulation with isoproterenol enhances left ventricular diastolic performance in hypertrophic cardiomyopathy despite potentiation of myocardial ischemia: comparison with rapid atrial pacing. Circulation 1989;79:371-382.

2. Udelson JE, Bonow RO, O'Gara PT, Maron BJ, Bacharach SL, Van Lingen A, Epstein SE. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic hypertrophic cardiomyopathy. Circulation 1989;79:1052-1060.

3. Brush JE, Udelson JE, Leon MB, Bacharach SL, Bonow RO. Comparative effects of verapamil and nitroprusside on left ventricular function in patients with hypertension. J Am Coll Cardiol 1989;14:515-522.

4. Labib S, Udelson JE, Pandian NG. Echocardiography in low pressure cardiac tamponade. Am J Cardiol 1989;63:1156-1157.

5. Udelson JE, Bacharach SL, Cannon RO, Bonow RO. Minimum left ventricular pressure during beta-adrenergic stimulation in human subjects: evidence for elastic recoil and diastolic "suction" in the normal heart. Circulation 1990;82:1174-1182.

6. Konstam MA, Kronenberg MW, Udelson JE, Metherall J, Dolan N, Edens T, Howe D, Yusuf S, Youngblood M, Toltsis H. Effect of acute angiotensin converting enzyme inhibition on early diastolic left ventricular filling in patients with congestive heart failure due to systolic dysfunction. Circulation 1990;81:III 115-122.

7. Cannon RO, Dilsizian V, O'Gara PT, Udelson JE, Schenke WH, Quyyumi A, Fananapazir L, Bonow RO. Myocardial metabolic, hemodynamic and electrocardiographic significance of reversible thallium-201 defects in hypertrophic cardiomyopathy. Circulation 1991;83:1660-1667.

8. Chuttani K, Pandian NG, Mohanty PK, Rosenfield K, Schwartz, SL, Udelson JE, Simonetti J, Kusay BS, Caldeira ME. Left ventricular diastolic collapse. An echocardiographic sign of regional cardiac tamponade. Circulation 1991;83:1999-2006.

9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.

10. Cannon RO, Dilsizian V, O'Gara PT, Udelson JE, Tucker E, Panza JA, Fananapazir L, McIntosh CL, Wallace RB, Bonow RO. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation 1992;85:1039-1045.

11. Konstam MA, Kronenberg MW, Udelson JE, Kinan D, Metherall J, Dolan N, Edens T, Howe D, Kilcoyne L, Benedict C, Youngblood M, Barrett J, Yusuf S. Effectiveness of Preload Reserve as a determinant of clinical status in patients with left ventricular systolic dysfunction. Am J Cardiol 1992;6:1591-1595.

12. Konstam MA, Rosseau MD, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H, for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor, enalapril, on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992;86:431-438.

11

13. Kimmelstiel CD, Udelson JE, Salem DN, Rastegar H, Bojar RM, Konstam MA. Recurrent angina due to a left internal mammary artery to pulmonary artery fistula. Am Heart J 1993;125:234-236.

14. Pouleur H, Rousseau MF, Van Eyll C, Stoleru L, Hayashida W, Udelson JE, Dolan N, Kinan D, Gallagher P, Ahn S, Benedict CR, Yusuf S, Konstam MA, for the SOLVD Investigators. Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. Circulation 1993;88:481-491.

15. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H, for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor, enalapril, on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation, 1993;88:2277-2283.

16. Rhodes J, Udelson JE, Marx GR, Schmid CH, Konstam MA, Hijazi ZM, Bova SA, Fulton DR. A new noninvasive method for the estimation of peak dP/dt. Circulation 1993;88:2693-2699.

17. Pouleur HG, Konstam MA, Udelson JE, Rousseau MF, for the SOLVD Investigators: Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. J Am Coll Cardiol 1993;22 [Supplement A]: 43A-48A.

18. Udelson JE, Coleman PS, Metherall J, Pandian NG, Gomez AA, Griffith JL, Shea NL, Oates E, Konstam MA. Predicting recovery of severe regional ventricular dysfunction: Comparison of resting scintigraphy with thallium201 and technetium 99m-sestamibi. Circulation, 1994;89:2552-2561.

19. Simons M, Parker JA, Udelson JE, Gervino EV. The impact of clinical data on interpretation of thallium scintigrams. J Nucl Cardiol 1994;1:365-371.

20. Bry JD, Belkin M, O'Donnell TF, Mackey WC, Udelson JE, Schmid CH, Safran DG. An assessment of the positive predictive value and cost-effectiveness of dipyridamole myocardial scintigraphy in vascular surgery patients. J Vasc Surg, 1994;19:112-24.

21. Wong ML, Achong DM, Udelson JE, Oates E. Technetium-99m sestamibi-avid pulmonary sclerosing hemangioma during myocardial perfusion imaging. Am J Noninvasive Cardiol 1994;8:106-108.

22. Udelson JE. Can Tc99m-sestamibi track myocardial viability? J Nucl Cardiol 1994;1:571-75.

23. Hijazi ZM, Udelson JE, Snapper H, Rhodes J, Marx GR, Schwartz SL, Fulton DR. Physiologic significance of chronic coronary aneurysms in patients with Kawasaki's disease. J Am Coll Cardiol. 1994;24:1633-1638.

24. Chuttani K, Metherall JA, Griffith JL, Oates E, Konstam MA, Pauker SG, Salem DN, Udelson JE. Enhanced hepatic uptake of thallium-201 in patients with severe narrowing of the right coronary artery. Am J Cardiol1995;76:1020-1024.

25. Du Bois J, Udelson JE, Atkins M. Severe reversible global and regional ventricular dysfunction associated with high dose interleukin - 2 immunotherapy. J Immunotherapy 1995;18:119-123.

26. Kimmelstiel C, Perrone R, Kilcoyne L, Souhrada J, Udelson JE, Smith JJ, de Bold A, Griffith J, Konstam M. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure. Cardiology 1996;87:46-53.

12

27. Packer M. Colucci WS, Sackner-Bernstein JD, Liang CS, Goldsher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 1996:2793-2799.

28. Snapper HJ, Shea NL, Konstam MA, Oates E, Udelson JE. Combined analysis of resting regional wall thickening and stress perfusion with electrocardiographic-gated technetium 99m-labeled sestamibi single-photon emission computed tomography: Prediction of stress defect reversibility. J Nucl Cardiol 1997;4:3-10.

29. Taillefer R, DePuey EG, Udelson JE, Beller GA, Latour Y, Reeves F. Comparative diagnostic accuracy of T1-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women. J Am Coll Cardiol 1997;29:69-77.

30. Patten RD, Kronenberg MW, Benedict CR, Udelson JE, Kinan D, Stewart D, Yusuf S, Smith JJ, Kilcoyne L, Dolan N, Edens TR, Metherall J, Konstam MA: Acute and chronic effects of the angiotensin converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction. Am Heart J. 1997;134:37-43.

31. Udelson JE, Criss D. Assessment of regional viability in the infarct zone following myocardial infarction. J Thrombosis and Thrombolysis 1997;4:207-216.

32. Shaw LJ, Hachamovitch R, Cohen M, Berman DS, Borges-Neto S, Udelson JE et al. Cost implications of selective pre-operative risk screening in the care of candidates for peripheral vascular operations. Am J Managed Care 1997;12:1817-27

33. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA: Effect of antiplatelet agents on survival in patients with left ventricular systolic dysfunction. J Am Coll Cardiol, 1998;31:419-25..

34. Al-Khadra A, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA: Effect of warfarin anticoagulation on survival in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 1998;31:749-53.

35. Kronenberg MW. Konstam MA. Edens TR. Howe DM. Dolan N. Udelson JE. Benedict C. Stewart D. Yusuf S. Factors influencing exercise performance in patients with left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction. J Cardiac Failure 1998;4:159-67.

36. Link MS. Wang PJ. Pandian NG. Bharati S. Udelson JE. Lee MY. Vecchiotti MA. VanderBrink BA. Mirra G. Maron BJ. Estes NA 3rd. An experimental model of sudden death due to low-energy chest-wall impact (commotio cordis) [see comments]. N Engl J Med 1998; 338:1805-11.

37. Taillefer R, DePuey G, Udelson JE, Beller GA, Benjamin C, Gagnon A. Comparison between the end-

diastolic images and the summed images of gated 99mTc-sestamibi SPECT perfusion study detection of coronary artery disease in women. J Nucl Cardiol 1999;6:169-76.

38. Kosnik JW. Zalenski RJ. Shamsa F. Harris R. Mittner J. Kozlowski J. Di Carli M. Udelson JE. Resting sestamibi imaging for the prognosis of low-risk chest pain. Academic Emergency Medicine 1999;6(10):998-1004.

39. Konstam MA, Patten, RD, Thomas I, Ramahi TM, LaBresh KA, Goldman S, Lewis WR, Gradman AH, Self KS, Bittner VA, Rand WH, Kinan DJ, Smith JJ, Ford TD, Segal R, Udelson JE. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J 2000 2000;139:1081-7

13

40. Udelson JE, DeAbate CA, Berk M, Neuberg G, Packer M, Vijay NK, Gorwitt J, Smith WB, Kukin ML, LeJemtel T, Levine TB, Konstam MA. Effects of amlodipine on exercise tolerance, quality of life and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J 2000;139:503-10

41. Laham RJ, Chronos NA, Pike, M, Leimbach ME, Udelson JE, Pearlman J, Pettigrew RI, Whitehouse MJ, Yoshizawa C, Simons M. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000;36:132–9

42. Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000 102: 1605-1610

43. Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, H. Hammond K, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE, Rosengart TK. Clinical trials in coronary angiogenesis: Issues, problems, consensus: An Expert Panel Summary. Circulation 2000 102: e73-e86

44. Patel AR, Kuvin JT, Pandian NG, Smith JJ, Udelson JE, Mendelsohn ME, Konstam MA, Karas RH. Heart failure etiology affects peripheral vascular endothelial function after cardiac transplantation. J Am Coll Cardiol 2001;37:195-200

45. Gregory D, Udelson JE, Konstam MA. Economic impact of beta-blockade in heart failure. Am J Med 2001;110 Suppl 7A: 74S-80S

46. Soman P, Taillefer R, DePuey EG, Udelson JE, Lahiri A. Enhanced detection of reversible perfusion defects by Tc-99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease. J Am Coll Cardiol 2001;37:458-462

47. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23

48. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001;141:899-907

49. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Rand WM, Udelson JE, Karas RH. Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol 2001;38:1843-9

50. Yao J, De Castro S, Delabays A, Masani N, Udelson JE, Pandian NG. Bulls-eye display and quantitation of myocardial perfusion defects using three-dimensional contrast echocardiography. Echocardiography 2001;18:581-8

51. Yao J, Takeuchi M, Teupe C, Sheahan M, Connolly R, Walovitch RC, Fetterman RC, Church CC, Udelson JE, Pandian NG. Evaluation of a new ultrasound contrast agent (AI-700) using two-dimensional and three-dimensional imaging during acute ischemia. J Am Soc Echocardiogr 2002:686-94

52. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002; 39:1151-8

14

53. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93

54. Udelson JE, Konstam MA. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Cardiac Failure 2003;8:S465-471

55. Udelson JE, Shafer CD. MIBG imaging for selecting heart failure patients for defibrillator therapy: a first step. Invited editorial. J Nucl Cardiol 2003 Mar-Apr 10: 2 208-10

56. Anand I, Florea VG, Solomon SD, Konstam MA, Udelson JE. Noninvasive assessment of left ventricular remodeling: Concepts, techniques, and implications for clinical trials. J Cardiac Failure 2003;8:S452-464

57. Udelson JE, Beshansky JR, Ballin DS, Feldman JA, Griffith JL, Heller GV, Hendel RC, Pope JH, Ruthazer R, Spiegler EJ, Woolard RH, Handler J, Selker HP. Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: A randomized, controlled trial. JAMA 2002;288:2693-2700

58. Kuvin, J., Patel, A., Sliney, K., Pandian, N., Sheffy, J., Schnall, R., Karas, R., Udelson, J. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003, 146: 168-174.

59. Patel AR, Kuvin JT, Denofrio D, Kinan D, Eranki KP, Pandian NG, Udelson JE, Konstam MA, Karas RH. Peripheral vascular endothelial function correlates with exercise capacity in cardiac transplant recipients. Am J Cardiol 2003;91:897-899.

60. Maron BJ, Estes NAM, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003;107:2872-2875.

61. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, O’Gara PT, Carabello BA, Russell RO, Cerqueira MG, St. John Sutton MG, DeMaria AN, Udelson JE, Kennedy JW, Verani MS, Williams KA. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003;42:1318-1333 and Circulation 2003; 108: 1404 - 1418.

62. Udelson JE, Heller GV, Wackers FJ, Chai A, Hinchman D, Coleman PS, Dilsizian V, DiCarli M, Hachamovitch R, Johnson JR, Barrett RJ, Gibbons RJ. Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacologic stress as an adjunct to myocardial perfusion imaging. Circulation 2004 109: 457-64

63. Kimmelstiel C, Levine D, Perry K, Patel AR, Sadaniantz A, Gorham N, Cunnie M, Duggan L, Cotter L, Shea-Albright P, Poppas A, LaBresh K, Forman D, Brill D, Rand W, Gregory D, Udelson JE, Lorell B, Konstam V, Furlong K, Konstam MA. Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial. Circulation 2004;110: 1450-5

64. Kapetanopoulos A, Heller GV, Selker HP, Ruthazer R, Beshansky JR, Feldman JA, Griffith JL, Hendel RC, Pope JH, Spiegler EJ, Udelson JE. Acute resting myocardial perfusion imaging in patients with

15

diabetes mellitus: results from the Emergency Room Assessment of Sestamibi for Evaluation of Chest Pain (ERASE Chest Pain) trial. J Nucl Cardiol 2004;11:570-7

65. Maron MS, Zenovich AG, Casey SA, Link MS, Udelson JE, Aeppli D, Maron BJ. Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy. Am J Cardiol 2005;95:1329–1333

66. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy.J Am Coll Cardiol 2005;46:480-7.

67. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with tolvaptan (EVEREST). J Card Failure 2005;11:260-9

68. Patten RD, Denofrio D, El-Zaru M, Kakkar R, Saunders J, Celestin F, Warner K, Rastegar H, Khabbaz KR, Udelson JE, Konstam MA, Karas RH. Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. J Am Coll Cardiol 2005;45:1419-24.

69. Dilsizian V, Bateman TM, Bergmann SR, Des Prez R, Magram MY, Goodbody AE, Babich JW, Udelson JE. Metabolic Imaging With -Methyl-p-[123I]-Iodophenyl-Pentadecanoic Acid (BMIPP) Identifies Ischemic Memory Following Demand Ischemia. Circulation 2005 (in press)

Invited Editorials

1. Udelson JE. Invited Editorial: Steps forward in the assessment of myocardial viability in left ventricular dysfunction. Circulation 1998;97:833-838

2. Udelson JE, Fares M. Invited Editorial. How accurate is gated SPECT imaging? J Nucl Med 2000

3. Udelson JE. Invited Editorial. Testing our tests: surrogate end points versus driving patient management and outcomes. J Am Coll Cardiol. 2001;37:89-92

4. Udelson JE, Selker HP. Invited Editorial. Quantitative instruments for predicting risk ... and benefit. J Am Coll Cardiol 2005 45(5):730-2.

5. Soman P, Udelson JE. Invited Editorial. Screening the population for coronary artery disease: is it like screening for cancer? J Nucl Cardiol 2005;12:145-7

16

Reviews in Journals

1. Udelson JE, Levine HJ. Timing of surgery for chronic aortic regurgitation: use of non-invasive tests. Primary Cardiology 1990;9:23-38.

2. Salem DN, Pandian NG, Udelson JE. Percutaneous balloon valvuloplasty and coronary angioplasty: what kind of guidance would be useful during the performance of these procedures? Echocardiography 1990;7:397-402.

3. Pandian NG, Weintraub A, Schwartz SL, Kumar R, Kusay BS, Katz SE, Aronovitz M, Udelson JE, Konstam MA, Salem DN, Kreis A. Intravascular and intracardiac ultrasound imaging: current research and future directions. Echocardiography 1990;7:377-387.

4. Smith J, Udelson JE, Salem DN, Konstam MA: Determinants of survival in patients with congestive heart failure. Cardio 1990; 7:34-42.

5. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Int Med 1992;117:502-510.

6. Udelson JE. Bonow RO. Diastolic dysfunction as a cause of heart failure. Hospital Practice 1993;28:49-56

7. Udelson JE. Interpreting cardiac imaging. Transactions of the American Academy of Insurance Medicine 1993;76:56-8.

8. Udelson JE. Book Review: Jablonski's Dictionary of Syndromes and Eponymic Diseases. N Engl J Med 1992;326:1646-1647.

9. Udelson JE. Choosing a thallium201 or Tc99m sestamibi imaging protocol. J Nucl Cardiol. 1994;1:S99-108.

10. Simons M, Parker JA, Udelson JE, Gervino EV. The role of clinical data in interpretation of perfusion images. J Nucl Med 1994;35:740-741.

11. Udelson JE, Surks H, Konstam MA. The importance of left ventricular diastolic dysfunction and right ventricular performance in the heart failure syndrome. Curr Opin in Cardiol 1993;8:383-396.

12. Udelson JE, Bonow RO. Diastolic dysfunction and congestive heart failure. Hosp Prac, 1993;28:49-56

13. Konstam MA, Smith JJ, Patten R, Udelson JE: Calcium channel blockers in heart failure: help or hindrance? J Card Failure 1996;2:S251-S257.

14. Udelson JE. Book review: Beller GA. Clinical Nuclear Cardiology. Circulation 1996;94:3008-9.

15. Schwartz B, Udelson JE. Assessment of myocardial viability by SPECT imaging in patients with chronic coronary artery disease. Revista de la Federacion Argentina de Cardiologia 1996;25:65-97.

16. Patten RD. Udelson JE. Konstam MA. Ventricular remodeling and its prevention in the treatment of heart failure. Current Opinion in Cardiology 1998;13:162-7.

17. Kimmelstiel CD, Udelson JE, Smith JJ, Konstam MA. Current concepts in the treatment of patients with heart failure. ACC Current Journal Review 1998:39-43.

17

18. Kim DC, Udelson JE. Is there a role for calcium-channel blockade in heart failure with systolic dysfunction? Eur Heart Journal

19. Bateman TM, Berman DS, Heller GV, Brown KA, Cerqueira MD, Verani MS, Udelson JE. American Society of Nuclear Cardiology position statement on electrocardiographic gating of myocardial perfusion SPECT scintigrams. J Nucl Cardiol 1999;6:470-1

20. Mieres JH. Udelson JE. Letter to the Editor: Meta-analysis of exercise testing to detect coronary artery disease in women Am J Cardiol 1999; 84:1454-6.

21. Bateman TM. Berman DS. Heller GV. Brown KA. Cerqueira MD. Verani MS. Udelson JE. American Society of Nuclear Cardiology position statement on electrocardiographic gating of myocardial perfusion SPECT scintigrams. J Nucl Cardiol 1999;6:470-1.

22. Wackers FJ, Brown KA, Heller GV, Kontos MC, Tatum JL, MD, Udelson JE, Ziffer JA. American Society of Nuclear Cardiology position statement on radionuclide imaging in patients with suspected acute ischemic syndromes in the emergency department or chest pain center. J Nucl Cardiol 2002;9:246-250

23. Anand IS, Florea VG, Solomon SD, Konstam MA, Udelson JE. Noninvasive assessment of left ventricular remodeling: Concepts, techniques, and implications for clinical trials. J Cardiac Failure 2002;8:S452-S464

24. Konstam MA, Udelson JE, Sharpe N. Prevention and reversal of left ventricular remodeling: summation. J Card Fail 2002: 6 Suppl S506-11

25. Udelson JE, Shafer CD, Carrio I. Radionuclide imaging in heart failure. Assessing etiology and outcomes and implications for management. J Nucl Cardiol 2002;9:42S-50S

26. Udelson JE, Patten RD, Konstam MA. New concepts in post-infarction ventricular remodeling. Rev Cardiovasc Med 2003 4 Suppl 3: S3-S12

27. Konstam MA, Udelson JE, Anand IS, Cohn JN Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail 2003;5:350-3

28. Fonarow GC, Abraham WT, Cannon CP, Gheorghiade M, Sackner-Bernstein JD, Udelson JE. Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction.Rev Cardiovasc Med 2003 4 Suppl 3: S54-9

29. Taylor AJ, Bairey Merz N, Udelson JE. 34th Bethesda Conference: Can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? J Am Coll Cardiol 2003;41: 1856-1858

30. Soman P, Udelson JE. Prognostic and therapeutic implications of myocardial viability in patients with heart failure. Curr Cardiol Rep 2004; 6:211-6

31. Taylor AJ, Udelson JE, Fuster V. Training cardiovascular fellows in cardiovascular magnetic resonance and vascular imaging; Current status following the core cardiovascular training symposium (COCATS-2) guidelines. J Am Coll Cardiol 2004;43:2108-12

32. Udelson JE. Ventricular remodeling in heart failure and the effect of beta-blockade. Am J Cardiol 2004;93:43B-8B

18

33. Udelson JE, Bonow RO, Dilsizian V. The historical and conceptual evolution of radionuclide assessment of myocardial viability. J Nucl Cardiol 2004;11:318-34

34. Udelson JE, Flint EJ. Radionuclide imaging in risk assessment after acute coronary syndromes. Heart 2004; 90 Suppl 5:6-25

35. Hedrich O, Finley J, Konstam MA, Udelson JE. Novel Neurohormonal Antagonist Strategies: Vasopressin antagonism, anti-cytokine therapy, and endothelin antagonism in patients with heart failure. Heart Failure Clinics of North America 2005 - in press

Monographs and Book Chapters

1. Konstam, MA, Udelson, JE: Right Heart Failure. In Hosenpud JD, Greenberg B.: Congestive Heart Failure: Pathophysiology, Differential Diagnosis and Comprehensive Approach to Therapy. New York, Springer-Verlag; 1993

2. Udelson JE, Bonow RO. Radionuclide ventriculography in left ventricular diastolic dysfunction. In: Gaasch WH, LeWinter M, eds. Heart Failure and Diastolic Dysfunction. Philadelphia: Lea & Febiger, 1994

3. Udelson JE, Bonow RO. Left ventricular diastolic function and the use of calcium channel blockers in hypertrophic cardiomyopathy. In: Gaasch WH, LeWinter M, eds. Heart Failure and Diastolic Dysfunction. Philadelphia: Lea & Febiger, 1994

4. Udelson JE, Leppo JA. Diagnosis of coronary artery disease. In: Murray and Ell, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingstone 1994.

5. Smith JJ, Udelson JE, Konstam MA, Salem DN: Use of the implantable cardioverter defibrillator in patients awaiting heart transplant. In Estes NAM, Manolis AS, Wang PJ: Implantable Cardioverter-Defibrillators. New York, Marcel Dekker; 1994.

6. Konstam MA, Udelson JE. Assessment of right ventricular function. In: Peterson KL, and Shabetai R, eds. Cardiac Catheterization: Methods, Diagnosis and Therapy. Philadelphia, W.B. Saunders. 1997.

7. Udelson JE. Use of technetium-99m agents for myocardial viability. In: Beller GA, Zaret BL. State-of-the-Art Nuclear Cardiology. Mosby.1998.

8. Corrodi JG, Udelson JE. Noninvasive imaging techniques to assess cardiac disease in the athlete In: Estes NAM, Salem DS, Wang P. Sudden Death in Athletes. Futura Publishing. 1998.

9. Udelson JE, Rajendran V, Leppo JA. Detection of coronary disease by SPECT imaging and radionuclide angiography. In: Murray and Ell, eds. Nuclear Medicine in Clinic Diagnosis and Treatment. 2nd Edition. 1998

10. Konstam MA, Udelson JE. Right heart failure. In: Hosenpud JD and Greenberg BH (eds): Congestive Heart Failure (second edition). Lippincott, New York, 1999.

11. Jafary F, Udelson JE. Assessment of myocardial perfusion and left ventricular function in acute coronary syndromes: Implications for gated SPECT imaging. In: Berman DS, Germano G, eds. Gated SPECT Imaging

19

12. Udelson JE. Emergency Department Imaging for Suspected Coronary Artery Disease. In: Advances in Cardiology. Braunwald E, ed., McGraw-Hill Cos., 2002

13. Udelson JE, Shafer CD, Venesy DM. Evaluation of patients with acute chest pain syndromes: Assessment with perfusion imaging in the Emergency Department. in: Nuclear Cardiac Imaging: Principals and Applications, 3rd Edition. Iskandrian AE and Verani MS, eds. Oxford University Press, 2002

14. Udelson JE. Radionuclide imaging in acute coronary syndromes. In: Dilsizian V, Narula J, eds. Braunwald’s Atlas of Nuclear Cardiology. 2003

15. Udelson JE, Dilsizian V, Bonow RO. Nuclear Cardiology. In: Braunwald’s Heart Disease, 7th Edition. Zipes DP, Libby P, Bonow RO, Braunwald E, eds. 2004

16. Hedrich O, Konstam MA, Udelson JE. Vasopressin and vasopressin antagonists in heart failure. In: Feldman A, ed. Pharmacotherapy of Heart Failure. 2005 – in press

17. Udelson JE. Radionuclide imaging in acute coronary syndromes. In: Dilsizian V, Narula J, eds. Braunwald’s Atlas of Nuclear Cardiology. 2nd Edition. 2005 – in press

Abstracts

1. Udelson JE, Cannon RO, Bacharach SL, Rumble TF, Bonow RO. Beta-adrenergic stimulation with isoproterenol enhances left ventricular diastolic performance in hypertrophic cardiomyopathy despite potentiation of myocardial ischemia. Circulation 1987;76:IV-513.

2. Udelson JE, Bonow RO, O'Gara PT, Bacharach SL, Van Lingen A, Epstein SE. Verapamil improves silent myocardial perfusion abnormalities in asymptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11:251A.

3. Udelson JE, Bacharach SL, Cannon RO, Bonow RO. Negative left ventricular pressure during beta-adrenergic stimulation in human subjects: evidence for diastolic "suction" in the normal heart. J Am Coll Cardiol 1988;11:34A.

4. Udelson JE, Bonow RO, Bacharach SL. Peak filling rate by radionuclide angiography: effect of normalization parameters. J Am Coll Cardiol 1987;9:4A.

5. Udelson JE, Maron BJ, O'Gara PT, Bonow RO. Relation between left ventricular hypertrophy, filling and perfusion in asymptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol 1989;13:80A.

6. Brush JE, Udelson JE, Leon MB, Bacharach SL, Bonow RO. Comparative effects of verapamil and

nitroprusside on left ventricular function in patients with hypertension. J Am Coll Cardiol 1988;11:37A.

7. Bacharach SL, Bonow RO, Udelson JE, Cannon RO, Green MV, Larson SM. Ventricular suction measurements by pressure/volume relations. J Nucl Med 1987;28:557.

8. Van Lingen A, Bacharach SL, Udelson JE, Bonow RO, Damske B, Green MV, Larson SM. SPECT error maps for improving thallium-201 quantitation. J Nucl Med 1987;28:631.

9. Udelson JE, Metherall J, Oates E, Konstam MA. Transient left ventricular dilatation during dipyridamole thallium scintigraphy: specific and predictive for multivessel coronary artery disease. J Nucl Med 1990;31:723

20

10. Konstam MA, Kronenberg MW, Udelson JE, Kinan D, Metherall J, Dolan N, Edens T, Howe D, Yusuf S, Youngblood M, Barrett JF, for the SOLVD Investigators. Preload reserve: a determinant of clinical status in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 1991;17:89A.

11. Weintraub AR, Sanzobrino B, Smith JJ, Udelson JE, et al. Intravascular ultrasound evaluation of acquired diseases of the aorta: aortography without contrast. American Society of Echocardiography 1991.

12. Daum RM, Cremisi HD, Yeager A, Udelson JE, Underhill D, Oates E. Mackey WC, O'Donnell TF, Konstam MA. Dipyridamole thallium imaging for determining perioperative and long-term prognosis in high risk vascular disease patients. Circulation 1988;78:II-191.

13. Brill DM, Konstam MA, Vivino PG, Udelson JE, Dolan N, Lane C, Turbett A, Metherall J, Kelly S, Salem DN. Importance of right ventricular systolic function as an independent predictor of mortality in patients with congestive heart failure. Circulation 1989;80:II-649.

14. Konstam MA, Kronenberg MW, Udelson JE, Metherall J, Dolan N, Edens T, Howe D, Yusuf S, Youngblood M, Toltsis H. Effect of angiotensin converting enzyme inhibition on left ventricular diastolic filling in patients with congestive heart failure: relation to right ventricular volumes. J Am Coll Cardiol 1990;15:210A.

15. Cannon RO III, O'Gara PT, Udelson JE, Bonow RO. Significance of reversible thallium perfusion defects in hypertrophic cardiomyopathy. Circulation 1989;80:II-662.

16. Coleman PS, Metherall JA, Farago PA, Oates E, Konstam MA, Udelson JE. Identification of ischemic myocardium with rest reinjection of thallium201 following dipyridamole stress-redistribution imaging. J Am Coll Cardiol 1991;17:29A.

17. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Kinan D, Ahn S, Yusuf S, Pouleur H, for the SOLVD Investigators. Effects of enalapril on the progression of left ventricular dysfunction in heart failure. Circulation 1991;84:II310.

18. Udelson JE, Konstam MA, Kronenberg MW, Pouleur H, Rousseau M, Kilcoyne L, Edens TR, Ahn S, Stewart D, Yusuf S, for the SOLVD Investigators. Effects of enalapril on right ventricular performance in patients with heart failure and left ventricular dysfunction. Circulation 1991;84:II311.

19. Kimmelstiel CD, Perrone RD, Kilcoyne L, Udelson JE, Smith JJ, de Bold AJ, Henry E, Souhrada JF, Konstam MA. Effects of renal endopeptidase inhibition on sodium excretion and renal hemodynamics in heart failure. J Am Coll Cardiol 1992;19:146A.

20. Konstam MA, Kronenberg MW, Udelson JE, Dolan N, Howe D, Kilcoyne L, Edens TR, Kinan D, Steward D, Salem DN, Yusuf S, for the SOLVD Investigators. Short-term effects following withdrawal from enalapril in patients with heart failure. J Am Coll Cardiol 1992;19:216A.

21. Zebede J, Clyne C, Udelson JE, Mandalakas N, Konstam M, Salem DN, Smith J, Kimmelstiel C, Butts L, Colburn C, Manolis A, Gadhoke A, Estes NAM, Wang PJ. Electrophysiologic effects of intracoronary quinidine infusion in humans. J Am Coll Cardiol 1992;19:220A.

22. Coleman PS, Metherall JA, Cao Q, Pandian N, Griffith JL, Shea NL, Oates E, Konstam MA, Udelson JE. Comparison of rest-redistribution thallium-201 uptake with resting sestamibi uptake in coronary artery disease. J Nucl Med 1992;33:905.

21

23. Coleman PS, Metherall JA, Pandian NG, Shea NL, Oates E, Konstam MA, Udelson JE. Predicting enhanced regional ventricular function post-revascularization: comparison of thallium201 and sestamibi in patients with left ventricular dysfunction. Circulation 1992;86:,I-108.

24. Udelson JE, Kronenberg MW, Rousseau MF, Stewart D, Pouleur H, Edens TR, Kilcoyne L, Kinan D, Ahn S, Konstam MA, for the SOLVD Investigators. Determinants of progressive left ventricular dilatation in patients with left ventricular systolic dysfunction. Circulation 1992;86:I-251.

25. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, Dolan N, Howe D, Kilcoyne L, Kinan D, Ahn S, Yusuf S, Pouleur H, for the SOLVD Investigators. Long-term effects of enalapril on left ventricular dilatation in asymptomatic patients with reduced ejection fraction: comparison with symptomatic patients. Circulation 1992;86:I-251.

26. Chuttani K, Metherall JA, Griffith JL, Pauker SG, Oates E, Coleman P, Salem DN, Konstam MA, Udelson JE. Hepatic uptake of thallium-201 chloride in patients with right coronary artery disease. Circulation 1992;86:I-579.

27. Hayashida W, Van Eyll C, Stoleru L, Rousseau MF, Konstam MA, Udelson JE, Melin J, Pouleur HG. Importance of the progressive changes in left ventricular diastolic chamber stiffness in patients with depressed systolic function. J Am Coll Cardiol 1993;21:400A.

28. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Metherall J, Kilcoyne L, Kinan D, Stewart D, Edens TR, Dolan N, Ahn S, Yusuf S, Pouleur H. Comparison of left ventricular remodeling and effects of enalapril in patients with ischemic versus non-ischemic etiology for systolic dysfunction. J Am Coll Cardiol 1993;21:131A.

29. Smith JJ, Shapiro L, Dolan NA, Kilcoyne LM, Udelson JE, Salem DN, Konstam MA, Dinarello A. Cytokine antagonists circulate in the blood of patients with advanced congestive heart failure. J Am Coll Cardiol 1993;21:268A.

30. Rhodes J, Udelson JE, Konstam MA, Marx GR, Hijazi ZM, Bova SA, Fulton DR. A new method for the estimation of peak dP/dt. J Am Coll Cardiol 1993;21:402A.

31. Wang PJ, Aronovitz M, Kinan D, Schoen FJ, Wight JN, Haugh CJ, Foote C, Gadhoke A, Konstam MA, Manolis A, Estes NAM, Udelson JE. Antimyosin antibody imaging for identification of catheter ablation induced myocardial necrosis. J Nucl Med 1993;34:65P.

32. Patten RD, Benedict CR, Kronenberg MW, Udelson JE, Steward D, Kilcoyne L, Dolan N, Yusuf S, Konstam MA, for the SOLVD Investigators: Effects of long-term enalapril on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction. Circulation 1993;88:I-293.

33. Hijazi ZM, Udelson JE, Snapper H, Rhodes J, Boyle MT, Schwartz S, Shea N, Marx GR, Bova S, Fulton DR. Physiologic significance of chronic coronary aneurysms in patients with Kawasaki disease. Circulation, 1993;88:I-12.

34. Gomez AA, Coleman PS, Metherall JA, Shea N, Oates E, Konstam MA, Udelson JE. Is reversibility of a resting thallium201 defect a necessary sign of myocardial viability? Circulation, 1993;88:I-534.

35. Ghali JK, Kronenberg MW, Udelson JE, Stewart D, Konstam MA, for the SOLVD investigators: Prognostic significance of right ventricular volumes in patients with left ventricular systolic dysfunction. Circulation, 1993;88:I-603.

22

36. Dipyridamole Safety Study Investigators. Safety of dipyridamole testing: preliminary results in 43,000 patients. J Am Coll Cardiol 1993;21:207A.

37. Dipyridamole Safety Study Investigators. Risk profile of dipyridamole testing in 64,000 patients. Eur Heart J 1993;14:461.

38. Dipyridamole Safety Study Investigators. How safe is dipyridamole testing? Eur J Nucl Med 1993;20:380.

39. Snapper HJ, Shea NL, Konstam MA, Oates E, Udelson JE. Combined analysis of regional wall motion and perfusion using gated SPECT sestamibi imaging: Prediction of stress defect reversibility. Circulation 1993;88:I-582.

40. Smith JJ, Shapiro L, Udelson JE, Salem DN, Konstam MA, Dinarello CA: Converting enzyme inhibitors do not influence cytokine antagonist levels in patients with left ventricular dysfunction. Circulation, 1993;88:I-294.

41. Rousseau MF, Benedict CR, Melin J, Ahn S, Konstam MA, Udelson JE, Dolan N, Kinan D, Stoleru L, Pouleur H, for the SOLVD Investigators: Lack of correlation between changes in plasma neuro-hormones and improvement in left and right ventricular function during long-term enalapril therapy. Euro Heart J. 1993;14 Abstr Suppl:10.

42. Flores EA, Pandian N, Schwartz S, Shea N, Konstam MA, Oates E, Udelson JE. Effect of nitroglycerin on sestamibi uptake in CAD and LV dysfunction and assessment of myocardial viability. J Am Coll Cardiol 1994;23:345A.

43. Conway LA, Pouleur H, Kronenberg MW, Rousseau MF, Udelson JE, Steward D, Yusuf S, Kinan D, Konstam MA for the SOLVD Investigators. Left ventricular volumes predict development of heart failure and potential clinical utility of ACE inhibitors in patients with asymptomatic systolic dysfunction J Am Coll Cardiol 1994;23:382A.

44. Conway LA, Smith JJ, Udelson JE, Kinan D, Turbett A, Kilcoyne L, Kronenberg MW, Konstam MA. Exercise capacity and cardiac performance after heart transplant: Importance of chronotropic incompetence. J Am Coll Cardiol 1994;23:417A.

45. Cheney PH, Bry JL, O'Donnell T, Mackey WC, Udelson JE. Long-term prognostic implications of perioperative myocardial infarction in patients undergoing vascular surgery. Circulation. 1994;90:I-95.

46. Daley L, Shea N, Oates E, Udelson JE. Stress-only myocardial perfusion imaging with Tc99m-sestamibi:Benign short-term prognosis of a streamlined perfusion imaging protocol. J Am Coll Cardiol, 1995.

47. Vannan M, Kettle A, Coakely A, Griffith J, Udelson JE. Influence of infarct zone viability on left ventricular remodeling in the year following first anterior myocardial infarction. Circulation 1995;92:I-286.

48. Patten R, Udelson JE, Smith JJ, Kimmelstiel CD, Kinan D, Konstam MA. Gender differences in exercise capacity in patients with left ventricular dysfunction. Circulation 1995;92:I-542

49. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Effect of antiplatelet agents on survival in patients with left ventricular dysfunction. Circulation 1995;92:I-665

23

50. Taillefer R, DePuey EG, Udelson JE, Beller G, Latour Y, Reeves F, Leonard S. Comparison of 201thallium and 99mTc-sestamibi (perfusion and gated SPECT) myocardial perfusion imaging in detection of coronary artery disease in women. Circulation 1995;92:I-129

51. Packer M, Colucci WS, Sackner-Bernstein J, Liang C, Udelson JE, Klapholz M. Prospective randomized evaluation of carvedilol on symptoms and exercise tolerance in chronic heart failure: results of the PRECISE trial. Circulation 1995;92:I-143

52. Udelson JE, DeAbate CA, Vijay N, Chrysant S, Goyle K, Loh I, Sklar J, Smith W, Konstam MA: Effects of amlodipine on exercise tolerance and quality of life in mild-to-moderate heart failure with systolic dysfunction. J Am Col Cardiol. 1996;27:280A.

53. Al-Khadra A, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA: Effect of warfarin anticoagulation on survival in patients with left ventricular systolic dysfunction. J Am Col Cardiol. 1996; 27:142A.

54. Vannan M, Kettle A, Coakely A, Udelson JE. Influence of infarct zone viability on regional and global ventricular geometry after anterior myocardial infarction. Circulation 1996;94:I-60.

55. Taillefer A, DePuey EG, Udelson JE, Beller GA, Miller DD, Watson D. Intraobserver variability of thallium-201 and Tc-99m sestamibi myocardial imaging in detection of CAD in women. J Nucl Med 1996;37:69P.

56. Taillefer R, DePuey EG, Udelson JE, et al. Sestamibi gated SPECT perfusion study in detection of coronary artery disease in women: comparison between the end-diastolic imaging and the summed images. J Nucl Cardiol 1997;4:S102.

57. Grossman AM, Miller DD, Udelson JE. Comparison of reinjection thallium201 and rest sestamibi for prediction of reversible regional left ventricular dysfunction. J Nucl Cardiol 1997;4:S23

58. Konstam MA, Thomas I, Ramahi TM, LaBresh KA, Goldman S, Lewis WR, Gradman AH, Self KS, Bittner VA, Rand WH, Kinan DJ, Smith JJ, Ford TD, Segal R, Udelson JE et al: Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Circulation 1997:96:I-452.

59. Ford TD, Corrodi JG, Smith JJ, Kinan DJ, Rastegar H, Udelson JE, Konstam MA: Early postoperative changes in hemodynamics and ventricular volumes and function following left ventricular reduction surgery. Circulation 1997;96:I-28.

60. Abadi CA, Vannan MA, Udeson JE, Anger E, Chilazi G, Pandian NG. Comparison of myocardial perfusion imaging using intravenous NC100100 B-mode harmonic, 2D echocardiography to SPECT sestamibi at an anatomic region and subject level in consecutive patients presenting with first myocardial infarction. Circulation 1998;98:I-569.

61. Nakata T, Kobayashi H, Miyamoto K. Ohiwa H, Noto T, Yamagishi M, Tsuchihashi K, Shimamoto K, Udelson JE. The correlation between myocardial perfusion and function regionally assessed by quantitative gated sestamibi tomography in acute myocardial infarction. J Am Coll Cardiol 1998;31:440A.

62. Patel AR, Kuvin J, Konstam MA, Smith JJ, Udelson JE, Patten RD, Pandian NG, Karas RH, Mendelsohn ME. Peripheral vascular endothelial function is abnormal after cardiac transplant but not in nonischemic cardiomyopathy. JACC 1999;33:176A.

24

63. Yao J, Takeuchi M, Teupe C, Sheahan M, Connolly R, Walovitch, Fetterman R, Church C, Udelson JE, Pandian N. A1-700, a new ultrasound contrast agent allows reliable detection of hypoperfused zones in acute ischemia and infarction not only in triggered mode but also in continuous imaging mode. J Am Coll Cardiol 1999;33:466A

64. Antonopoulos GV, Lau J, Konstam MA, Udelson JE: Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure? J Card Failure 1999;5 (Suppl 1):47.

65. Udelson JE, Miller D, Schusterman N, Konstam MA: Are observation periods necessary during initiation and uptitration of carvedilol in heart failure? J Card Failure 1999;5 (Suppl 1):54.

66. Antonopoulos GV Lau J, Konstam MA, Udelson JE: Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure? Circulation 1999;100:I-296.

67. Patel AR, Kuvin JT, Smith JJ, Udelson JE, Karas RH, Mendelsohn ME, Konstam MA: Peripheral vascular endothelial dysfunction normalizes after cardiac transplantation in nonischemic cardiomyopathy but persists in ischemic cardiomyopathy. Circulation 1999;100:I-784.

68. Soman P, Taillfer R, Udelson JE, DePuey GE, Lahiri A. Superiority of Tc-99m sestamibi over Tc-99m tetrofosmin for the assessment of mild to moderate coronary artery disease with vasodilator stress SPECT: a prospective multicentre study. Circulation 1999;110:I-661.

69. Laham J, Chronos NAF, Leimbach ME, Pearlman JD, Pettigrew R, Dilsizian V, Udelson JE, Whitehouse MJ, Pike M, Yoshizawa C, Simons M. Results of a phase I open label dose escalation study of intracoronary and intravenous basic fibroblast growth factor (rFgF-2) in patients with severe ischemic heart disease: six month follow up. J Am Coll 2000;35:73A.

70. Udelson JE, Dilsizian V, Laham RJ, Chronos NAF, Vansant PJ, Whitehouse MJ, Pike M, Yoshizawa C, Simons M. Reduction in stress myocardial ischemia by basic fibroblast growth factor (rFGF-2) in severe ischemic heart disease. J Am Coll Cardiol 2000;35:74A.

71. Choi SW, Udelson JE, Ruthazer R, Beshansky JR, Selker HP. Does symptom onset in the morning help predict the diagnosis of acute cardiac ischemia? J Am Coll Cardiol 2000;35:405A.

72. Painchaud CA, Ghazzi MM, Selaru P, Bichet DG, Chartier KK, Udelson JE. Urinary water clearance after infusion of conivaptan, a combined vassopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure. Circulation 2000;100:II-535.

73. Udelson JE, Antonopoulos GV, Proulx G, Sussez BA, Arnold JM, Kouz S, Mehta SS, Kontam MA. Comparison of long-term dual vasopeptidase inhibition with omapatrilat to ACE inhibition with lisinopril on ventricular volumes in patients with heart failure. Circulation 2000;100:II-536.

74. Hendel RC, Udelson JE, Beshansky JR, Ruthazer R, Griffith JL, Heller GV, Pope JH, Selker HP. Does the absence of active chest pain at the time of Tc99m sestamibi injection affect the value of rest Tc99m sestamibi imaging for emergency department patients with acute chest pain? Circulation 2000;100:II-543.

75. Hendel RC, Selker HP, Heller GV, Ruthazer R, Beshansky JR, Griffith JL, Udelson JE. The impact of attenuation correction and gating on SPECT perfusion imaging in patients presenting to the emergency department with chest pain. Circulation 2000;100:II-543.

25

76. Heller GV, Udelson JE, Ruthazer R, Beshansky JR, Pope HJ, Giri S, Hendel RC, Woodword R, Griffith JL, Ahlberg AW, Selker HP. Acute rest myocardial perfusion imaging is useful in the evaluation of diabetic patients: results from the ERASE chest pain trial. Circulation 2000;100:II-544.

77. Allman KC, SHAW LJ, Hachamovitch R, Udelson JE. Prognostic value of myocardial viability testing: a meta-analysis. Circulation 2000;100:II-576.

78. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi MM, Thomas I, Ghali JK, Selaru P, Pressler ML, Konstam M. Hemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1a and V2 receptor antagonist in patients with advanced heart failure. Circulation 2000;100-II-593.

79. Smith WB, Russell S, Ghali JK, Painchaud CA, Selaru P, Ghazzi MM, Konstam MA, Udelson JE. Conivaptan (CI-1025, YM087), a Combined Vasopressin V1A/V2 Receptor Antagonist, Reduces Pulmonary Capillary Wedge Pressure Independent of Baseline Serum Sodium or Vasopressin Levels in Heart Failure Patients. J Am Coll Cardiol 2001;37:172A

80. Udelson JE, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Packer M. Comparative Effects of Metoprolol and Carvedilol on Left Ventricular Function in Heart Failure. J Am Coll Cardiol 2001;37:184A

81. Kuvin JT, Patel AR, Sliney KA, Sheffy J, Schnell RP, Pandian NG, Karas RH, Udelson JE. Peripheral Arterial Tonometry: A simplified technique for assessing endothelium-dependent vasomotion. J Am Coll Cardiol 2001;37:243A

82. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Udelson JE, Karas RH. Relation between impaired peripheral endothelial function and abnormal exercise myocardial perfusion. J Am Coll Cardiol 2001;37:250A

83. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Udelson JE, Karas RH. Peripheral vascular endothelial function predicts exercise tolerance. Circulation 2001;104:II-328

84. Patten R, El-Zaru M, Denofrio D, Konstam MA, Udelson JE, et al. Left ventricular assist device therapy normalizes inducible nitric oxide synthase expression in failing human hearts. Circulation 2001;104:II-357

85. Gheorghiade M, Orlandi C, Gottlieb S, Corder C, Udelson JE, Ouyang J, Konstam MA. Vasopressin V2 receptor blockade versus fluid restriction in the treatment of hyponatremia: results from a multicenter randomized controlled trial. Circulation 2001;104:II-438

86. Hendel RC, Gupta A, Ruthahzer R, Selker HP, Heller GV, Pope JH, Woolard, RH, Beshansky JR, Udelson JE. The impact of gender on the diagnostic and prognostic value of myocardial perfusion imaging in patients with acute chest pain. Circulation 2001;104:II-455

87. Patel AR, Kuvin JT, Denofrio D, Kinan D, Sliney KA, Eranki KP, Pandian NG, Udelson JE, Konstam MA, Karas RH. Peripheral vascular endothelial function predicts exercise capacity in cardiac transplant recipients. J Am Coll Cardiol 2001;39:145A

88. Udelson JE, Orlandi C, O’Brien T, Sequiera R, Ouyang J, Konstam MA. Vasopressin receptor blockade in patients with congestive heart failure: Results from a placebo-controlled, randomized study comparing the effects of tolvaptan, furosemide and their combination. J Am Coll Cardiol 2001;39:156A

26

89. Gheorghiade M, Konstam MA, Udelson JE, Ouyang J Orlandi C. Vasopressin receptor blockade with tolvaptan in chronic heart failure: Differential effects in normonatremic and hyponatremic patients. J Am Coll Cardiol 2001;39:171A

90. Gupta A, Hendel RC, Ruthahzer R, Heller GV, Selker HP, Beshansky JR, Pope JH, Woolard, RH, Udelson JE. Management and outcome of acute chest pain: influence of age and the use of SPECT myocardial perfusion imaging. . J Am Coll Cardiol 2001;39:344A

91. Gupta A, Hendel RC, Ruthazer R, Heller GV, Selker HP, Beshanski J, Udelson JE. Management and outcome of acute chest pain: influence of age and the use of SPECT myocardial perfusion imaging. J Am Coll Cardiol 2002;39, Supplement 2

92. Patel AR, Kuvin JT, DeNofrio D, Kinan D, Sliney KA, Pamdian NG, Udelson JE, Karas R. Peripheral vascular endothelial function predicts exercise capacity in cardiac transplant recipients. J Am Coll Cardiol 2002;39, Supplement 2

93. Udelson JE, Orlandi C, O'Brien T, Sequeira R, Ouyang J, Zimmer C, Konstam MA. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination. J Am Coll Cardiol 2002;39, Supplement 2

94. Gheorghiade M, Konstam MA, Udelson JE, Ouyang J, Orlandi C. Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients. J Am Coll Cardiol 2002;39, Supplement 2

95. Kuvin, J., Patel, A., Sliney, K., Sheffy, J., Schnall, R., Pandian, N., Karas, R., Udelson, J. Peripheral Arterial Tonometry During Hyperemia is Blunted in Patients With Coronary Artery Disease. J Am Coll Cardiol 2003; 41:269A.

96. Johnson JR, Barrett R, Udelson JE, Hachamovitch R, Massaro J. Application of trial simulation for estimating the clinical event outcome rates following pharmacologic stress SPECT imaging. J Nucl Cardiol 2003;10:S33

97. Hachamovitch R, Barrett R, Haught H, Lim C, Underwood R, Jenkins S, Johnson J, Udelson JE. Populations presenting for a myocardial perfusion imaging study: Results from an international study of utilization and outcomes following pharmacologic stress SPECT imaging.J Nucl Cardiol 2004;11: S28

98. Hachamovitch R, Johnson J, Barrett Rj R, Jenkins S, Massaro J, Udelson JE. Design and rationale for an international study of utilization and outcomes following pharmacologic stress SPECT imaging. J Nucl Cardiol 2004:S27-8

99. Udelson JE, Barrett RJ, Johnson J, Menenghetti C, Taillefer R, Ruddy T, Hachamovitch R. Distribution of ischemia and fixed perfusion defects detected in an international, observational, study of pharmacologic stress spect myocardial perfusion imaging. J Nucl Cardiol 2004;11: S27

27